1. Home
  2. LNKB vs GNFT Comparison

LNKB vs GNFT Comparison

Compare LNKB & GNFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LNKB
  • GNFT
  • Stock Information
  • Founded
  • LNKB 2018
  • GNFT 1999
  • Country
  • LNKB United States
  • GNFT France
  • Employees
  • LNKB N/A
  • GNFT N/A
  • Industry
  • LNKB
  • GNFT Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • LNKB
  • GNFT Health Care
  • Exchange
  • LNKB Nasdaq
  • GNFT Nasdaq
  • Market Cap
  • LNKB 284.4M
  • GNFT 190.6M
  • IPO Year
  • LNKB N/A
  • GNFT 2019
  • Fundamental
  • Price
  • LNKB $7.50
  • GNFT $3.81
  • Analyst Decision
  • LNKB Hold
  • GNFT Strong Buy
  • Analyst Count
  • LNKB 1
  • GNFT 1
  • Target Price
  • LNKB $7.50
  • GNFT $13.00
  • AVG Volume (30 Days)
  • LNKB 75.7K
  • GNFT 7.8K
  • Earning Date
  • LNKB 01-27-2025
  • GNFT 09-19-2024
  • Dividend Yield
  • LNKB 3.95%
  • GNFT N/A
  • EPS Growth
  • LNKB 61.51
  • GNFT N/A
  • EPS
  • LNKB 0.17
  • GNFT 0.47
  • Revenue
  • LNKB $86,138,000.00
  • GNFT $86,225,222.00
  • Revenue This Year
  • LNKB N/A
  • GNFT $155.44
  • Revenue Next Year
  • LNKB $9.49
  • GNFT N/A
  • P/E Ratio
  • LNKB $45.20
  • GNFT $7.69
  • Revenue Growth
  • LNKB 151.51
  • GNFT 175.45
  • 52 Week Low
  • LNKB $5.86
  • GNFT $3.31
  • 52 Week High
  • LNKB $8.29
  • GNFT $6.42
  • Technical
  • Relative Strength Index (RSI)
  • LNKB 47.16
  • GNFT 32.66
  • Support Level
  • LNKB $7.53
  • GNFT $3.63
  • Resistance Level
  • LNKB $7.78
  • GNFT $3.76
  • Average True Range (ATR)
  • LNKB 0.20
  • GNFT 0.12
  • MACD
  • LNKB -0.05
  • GNFT 0.04
  • Stochastic Oscillator
  • LNKB 21.70
  • GNFT 18.77

About LNKB LINKBANCORP Inc.

Linkbancorp Inc operates in the banking industry. It provides banking services for individuals and businesses such as commercial lending, non-profit banking, treasury management, deposits and loans.

About GNFT GENFIT S.A.

Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of innovative medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.

Share on Social Networks: